Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)
Study Details
Study Description
Brief Summary
This study will be the first to evaluate the dose-dependent effects of t-PBM in amnestic Mild Cognitive Impairment (aMCI) (CDR of 0.5-1, FAST 1-3; age 65-85) in a randomized clinical trial of 8 weeks of t-PBM vs. sham. At screening, all subjects will complete initial neuropsychological testing. To elucidate mechanisms of action of t-PBM, prior to treatment, subjects will undergo neuroimaging related to critical features of AD: tau 18F MK-6240 load (PET), measures of brain bioenergetics (31P-MRS), and functional connectivity (rs-fMRI). Subjects will also undergo an open label t-PBM session performed during fMRI to detect BOLD changes with t-PBM. Subjects will then be randomized to t-PBM/sham and complete treatments in two participating centers (NYU/NKI acting as a single center, and MGH), ~10 min per day, 3 days per week, for 8 weeks. t-PBM will be administered via pulsed, 808nm wavelength laser delivery to the forehead bilaterally (at standard EEG electrode positions F4, F3).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Transcranial Photobiomodulation (t-PBM)
|
Device: Active tPBM-2.0
The NIR pulsed wave (irradiance =300 mW/cm2) will be used. The duration or irradiation will be for ~11 minutes (666 seconds).
Drug: 18F-MK-6240
PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments
|
| Sham Comparator: Sham
|
Device: Sham tPBM-2.0
The sham mode (0 mW/cm2) will be used. The duration or sham "irradiation" will be for ~11 minutes (666 seconds).
Drug: 18F-MK-6240
PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments
|
Outcome Measures
Primary Outcome Measures
- Change in Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS) Total Scale Index Score. [Baseline, Week 8]
RBANS is s a brief, individually administered battery to measure cognitive decline or improvement. Total Scale Index Score Range = 40-160. A higher score indicates better performance.
Secondary Outcome Measures
- Change in Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS) Total Scale Index Score. [Baseline, Month 3]
RBANS is s a brief, individually administered battery to measure cognitive decline or improvement. Total Scale Index Score Range = 40-160. A higher score indicates better performance.
- Addenbrooke's Cognitive Examination (ACE-III) Score [Baseline]
ACE-III is a screening test that is composed of tests of attention, orientation, memory, language, visual perceptual and visuospatial skills. The total range of raw score is 0-100. A higher score indicates more intact cognitive functioning.
- Addenbrooke's Cognitive Examination (ACE-III) Score [Week 8]
ACE-III is a screening test that is composed of tests of attention, orientation, memory, language, visual perceptual and visuospatial skills. The total range of raw score is 0-100. A higher score indicates more intact cognitive functioning.
- Addenbrooke's Cognitive Examination (ACE-III) Score [Month 3]
ACE-III is a screening test that is composed of tests of attention, orientation, memory, language, visual perceptual and visuospatial skills. The total range of raw score is 0-100. A higher score indicates more intact cognitive functioning.
- Letter Comparison Test Score [Baseline]
The total range of score is 0-21. A higher raw score indicates better performance.
- Letter Comparison Test Score [Week 8]
The total range of score is 0-21. A higher raw score indicates better performance.
- Letter Comparison Test Score [Month 3]
The total range of score is 0-21. A higher raw score indicates better performance.
- Pattern Comparison Test Score [Baseline]
The total range of score is 0-30. A higher raw score indicates better performance.
- Pattern Comparison Test Score [Week 8]
The total range of score is 0-30. A higher raw score indicates better performance.
- Pattern Comparison Test Score [Month 3]
The total range of score is 0-30. A higher raw score indicates better performance.
- Stroop Color and Word Test (SCWT) [Baseline]
SCWT is a neuropsychological test extensively used to assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect. This study will use T-scores, range = 20 - 80. A higher T-score indicates better performance.
- Stroop Color and Word Test (SCWT) [Week 8]
SCWT is a neuropsychological test extensively used to assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect. This study will use T-scores, range = 20 - 80. A higher T-score indicates better performance.
- Stroop Color and Word Test (SCWT) [Month 3]
SCWT is a neuropsychological test extensively used to assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect. This study will use T-scores, range = 20 - 80. A higher T-score indicates better performance.
- Difference in Score Between Trail Making Test-A (TMT-A) and Trail Making Test-B (TMT-B) [Baseline]
Trails Making Test (Trails) is a neuropsychological test of visual attention and task switching. Both parts of the Trail Making Test consist of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1-25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1-13) and letters (A-L); as in Part A, the patient draws lines to connect the circles in an ascending pattern (alternating numbers and letters). The time it takes to connect the "trail" is recorded. Reported as B - A. Range = 0 - 100+ (measured in seconds). A higher B - A score indicates poorer performance.
- Difference in Score Between Trail Making Test-A (TMT-A) and Trail Making Test-B (TMT-B) [Week 8]
Trails Making Test (Trails) is a neuropsychological test of visual attention and task switching. Both parts of the Trail Making Test consist of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1-25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1-13) and letters (A-L); as in Part A, the patient draws lines to connect the circles in an ascending pattern (alternating numbers and letters). The time it takes to connect the "trail" is recorded. Reported as B - A. Range = 0 - 100+ (measured in seconds). A higher B - A score indicates poorer performance.
- Difference in Score Between Trail Making Test-A (TMT-A) and Trail Making Test-B (TMT-B) [Month 3]
TMT is a neuropsychological test of visual attention and task switching. Both parts of the Trail Making Test consist of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1-25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1-13) and letters (A-L); as in Part A, the patient draws lines to connect the circles in an ascending pattern (alternating numbers and letters). The time it takes to connect the "trail" is recorded. Reported as B - A. Range = 0 - 100+ (measured in seconds). A higher B - A score indicates poorer performance.
- TMT-B T-Score [Baseline]
In TMT-B, the circles include both numbers (1-13) and letters (A-L); the patient draws lines to connect the circles in an ascending pattern (alternating numbers and letters). The time is takes to connect the "trail" is recorded. Range = 0 - 100. A higher T-score indicates better performance
- TMT-B T-Score [Week 8]
In TMT-B, the circles include both numbers (1-13) and letters (A-L); the patient draws lines to connect the circles in an ascending pattern (alternating numbers and letters). The time is takes to connect the "trail" is recorded. Range = 0 - 100. A higher T-score indicates better performance
- TMT-B T-Score [Month 3]
In TMT-B, the circles include both numbers (1-13) and letters (A-L); the patient draws lines to connect the circles in an ascending pattern (alternating numbers and letters). The time is takes to connect the "trail" is recorded. Range = 0 - 100. A higher T-score indicates better performance
- Face-Name Associative Memory Exam (FNAME-12) Score [Baseline]
FNAME-12 is an associative memory test where participants see a series of facial photos and names and are asked to remember the face-name pairs.
- Face-Name Associative Memory Exam (FNAME-12) Score [Week 8]
FNAME-12 is an associative memory test where participants see a series of facial photos and names and are asked to remember the face-name pairs.
- Face-Name Associative Memory Exam (FNAME-12) Score [Month 3]
FNAME-12 is an associative memory test where participants see a series of facial photos and names and are asked to remember the face-name pairs.
- Letter Number Sequencing Score [Baseline]
this study will use T-scores, range = 20 - 80. A higher T-score indicates better performance.
- Letter Number Sequencing Score [Week 8]
this study will use T-scores, range = 20 - 80. A higher T-score indicates better performance.
- Letter Number Sequencing Score [Month 3]
this study will use T-scores, range = 20 - 80. A higher T-score indicates better performance.
- Change in Systemic Assessment for Treatment Emergent Events - Specific Inquiry (SAFTEE-SI) Score [Baseline, up to Week 8]
SAFTEE-SI is a list of 55 symptoms. Participants indicate how bothersome each symptom has been for them by circling the appropriate number (0-none, 1-mild, 2-moderate, 3-severe). The total range of score is 0 - 165. The higher the score, the more severely bothersome the symptoms are.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Able to give written informed consent and follow study procedures.
-
Age ≥ 65 years and ≤ 85 years.
-
Meets the Petersen MCI criteria for Amnestic MCI (single and multiple domain) with a Clinical Dementia Rating (CDR) between 0.5 to 1, and a Functional Assessment Staging (FAST) of 1-3.
-
Consents to permit and identifies a willing informed relative, family member, or spouse for study staff to interview to confirm subject reports as per UDS 3.0 guidelines.
-
Have at least a high school diploma / 12 years education
Exclusion Criteria:
-
Unwilling/unable to comply with study procedures.
-
Other diagnosis of dementia (i.e., not Alzheimer's type), history of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, intellectual disability, or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
-
History of significant cardiovascular or cerebrovascular pathology (e.g., myocardial infarction; stroke).
-
Clinically unstable systemic medical disorders.
-
Current DSM-5 diagnosis of alcohol or drug use disorder or other major psychiatric illness (e.g., schizophrenia, bipolar, PTSD, depression).
-
Clinical or laboratory evidence of hypothyroidism.
-
Clinically significant abnormal findings of laboratory parameters or at physical examination.
-
Medications affecting cognition (e.g., narcotic analgesics; chronic use of medications with anticholinergic activity, anti-Parkinsonian medications, antipsychotic meds, etc.). Stable use (i.e., ≥ 6 months) of memantine or acetylcholinesterase inhibitors will be allowed.
-
Family history of early onset (<60 y/o) dementia.
-
Body size and shape not allowing for a comfortable fit in PET and MRI scanners.
-
Past intolerance or hypersensitivity to t-PBM.
-
Significant skin conditions on the subject's scalp in the area of the procedure sites.
-
Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment.
-
Any type of implants in the head, whose functioning might be affected by t-PBM, or any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
-
Claustrophobia or metallic foreign bodies that would preclude MRI.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02114 |
| 2 | NYU Langone Health | New York | New York | United States | 10016 |
| 3 | Nathan Kline Institute | Orangeburg | New York | United States | 10962 |
Sponsors and Collaborators
- NYU Langone Health
- Alzheimer's Association
- National Institutes of Health (NIH)
- LiteCure LLC
Investigators
- Principal Investigator: Dan Iosifescu, MD, NYU Langone Health and Nathan Kline Institute
- Principal Investigator: Ricardo Osorio, MD, NYU Langone Health and Nathan Kline Institute
- Principal Investigator: Paolo Cassano, MD, PhD, Massachusetts General Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 20-00865